Drug-Eluting stents offer no advantage for A-Fib patients

June 22, 2012
Drug-Eluting stents offer no advantage for A-Fib patients
Drug-eluting stents do not seem to offer advantages over bare-metal stents for patients with atrial fibrillation who undergo percutaneous coronary intervention with stent implantation, according to research published in the July 1 issue of The American Journal of Cardiology.

(HealthDay) -- Drug-eluting stents (DESs) do not seem to offer advantages over bare-metal stents (BMSs) for patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) with stent implantation, according to research published in the July 1 issue of The American Journal of Cardiology.

Laurent Fauchier, M.D., Ph.D., of the Université François Rabelais in Tours, France, and colleagues compared the efficacy and safety of DESs with BMSs in 833 consecutive unselected patients with AF, seen from 2000 to 2010, who had undergone PCI with stent implantation.

Of the stents implanted, 81 percent were BMSs and 19 percent were DESs. During a median follow-up of 688 days, the researchers found that the incidence of all-cause mortality and of major adverse cardiac events (MACEs; death, acute myocardial infarction, target lesion revascularization) was similar between the two groups. The results remained similar after adjustment for confounders and age. Older age, implantation of stent during acute ST-segment elevation myocardial infarction, and stent diameter were significantly and independently associated with an increased risk of MACEs. DESs did not correlate with a higher risk of bleeding, and the ratio of serious events at follow-up was similar for DES and BMS implantation.

"In conclusion, in our cohort, systematic use of DESs does not seem to be justified in most patients with AF because it was not associated with any clear advantage compared to BMSs," the authors write.

Explore further: Good long-term outcomes for drug-eluting stents

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Good long-term outcomes for drug-eluting stents

April 4, 2012
(HealthDay) -- Meta-analysis of randomized clinical trials (RCTs) suggests that drug-eluting stents (DESs) significantly reduce repeat revascularizations, with no increase in stent thrombosis (ST), mortality, or recurrent ...

Considerably lower risk of stent thrombosis and restenosis in 'new generation' drug-eluting stents

August 30, 2011
Results from the SCAAR study, presented at the ESC Congress 2011 today, showed that Percutaneous Coronary Intervention (PCI) with "new generation" Drug Eluting Stents, was associated with a 38% lower risk of clinically meaningful ...

Long-term outcome similar with thrombus aspiration and stents in PCI

May 2, 2012
New research confirms thrombus aspiration (TA) during percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) provides long-term outcomes similar to conventional ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.